Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orlistat

Study Exploring the Supportive Effect of Acarbose in Weight Management

Empros Pharma AB · Phase 2 · Status n/r · Enrollment 320

NCT05934110

EudraCT 2022-003320-40

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
EMP16-120/40n/rn/rn/rn/r
MR orlistatn/rn/rn/rn/r
Conventional orlistatn/rn/rn/rn/r
EMP16-60/20n/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • EMP16-120/40: endpoint not reported
  • MR orlistat: endpoint not reported
  • Conventional orlistat: endpoint not reported
  • EMP16-60/20: endpoint not reported
  • Placebo: endpoint not reported